Literature DB >> 2575509

The uptake of clodronate (dichloromethylene bisphosphonate) by macrophages in vivo and in vitro.

J Mönkkönen1, A Urtti, P Paronen, H A Elo, P Ylitalo.   

Abstract

Clodronate (dichloromethylene bisphosphonate) accumualtes extensively in the bone by binding to apatite crystals. We found recently that the drug also accumulates in the spleen and, to a lesser extent, in the liver of mice and rats. In the present study, the role of macrophages in soft tissue accumulation was studied in mice by autoradiography and macrophage-depleting techniques, and also by isolated rat peritoneal macrophages. The localization of [14C]clodronate in mouse spleen showed that the drug concentrates in the marginal zone between the white and red pulp, which is known to be rich in macrophages. Pretreatment of mice with pure clodronate did not change the accumulation of [14C]clodronate in the spleen. However, when splenic and hepatic macrophages were eliminated by the liposome-encapsulated clodronate, only a weak [14C]clodronate accumulation occurred in these organs. Isolated macrophages did not take up free [14C]clodronate, but the addition of ferrous iron to the incubate resulted in the uptake of 14C activity by macrophages. They were probably stimulated by the insoluble clodronate-iron complex. The results suggest that 1) macrophages are involved in the accumulation of clodronate in the spleen and liver, and 2) combination of clodronate with extracellular iron is a prerequisite for the activation of macrophages to take up the drug complex. Since the spleen and, to a lesser extent, the liver are rich in iron released from destroyed red cells, accumulation of clodronate takes place in these organs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2575509

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

Review 1.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  Relationship between physicochemical and osteotropic properties of bisphosphonic derivatives: rational design for osteotropic drug delivery system (ODDS).

Authors:  H Hirabayashi; T Sawamoto; J Fujisaki; Y Tokunaga; S Kimura; T Hata
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

Review 3.  Extracellular and intracellular action of clodronate in osteolytic bone diseases? A hypothesis.

Authors:  N van Rooijen
Journal:  Calcif Tissue Int       Date:  1993-06       Impact factor: 4.333

4.  The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice. The effects of vehicle and the route of administration.

Authors:  J Mönkkönen; P Ylitalo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

5.  The effects of liposome-encapsulated and free clodronate on the growth of macrophage-like cells in vitro: the role of calcium and iron.

Authors:  J Mönkkönen; T D Heath
Journal:  Calcif Tissue Int       Date:  1993-08       Impact factor: 4.333

Review 6.  Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.

Authors:  Hideki Hirabayashi; Jiro Fujisaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 7.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

8.  New strategies to prolong the in vivo life span of iron-based contrast agents for MRI.

Authors:  Antonella Antonelli; Carla Sfara; Serafina Battistelli; Barbara Canonico; Marcella Arcangeletti; Elisabetta Manuali; Sonia Salamida; Stefano Papa; Mauro Magnani
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.